Drug Development

Articles

The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Dyadic International Selected for COVID-19 Vaccine Candidate Development

The companies have entered into a development and manufacturing agreement for Anthos Therapeutics’ abelacimab for treating thrombotic disorders.

Lonza, Anthos Therapeutics Partner on Anti-coagulant Biologic Abelacimab

Catalent will use its GPEx cell line development technology to create a cell line expressing the recombinant VLP at its Madison, WI facility. 

Catalent Partners with Spicona for COVID-19 Vaccine Development

Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate. 

Novavax Secures $60 Million in Government Funds

The European Commission is pledging EUR 300 million (US$339 million) to Gavi for vaccines for infectious diseases, in addition to an earlier pledge of more than EUR 1.5 billion (US$1.7 billion) made on May 4, 2020.

EC Pledges Nearly $340 Million Additional Vaccine Funding to Gavi

The European Commission has granted marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for Darzalex (daratumumab) subcutaneous formulation to treat adults with multiple myeloma.

EC Grants Marketing Authorization for Subcutaneous Formulation of Daratumumab

CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.

CordenPharma Expands Lipid Supply for Moderna

The investment will give the company the opportunity to accelerate the development of proprietary boron-10 target drugs while it develops its neutron beam accelerator technology for Boron Neutron Capture Therapy.

TAE Life Sciences to Launch Drug Delivery Program After $30-Million Investment

The new vaccine would be made with a Newcastle disease virus vector that expresses the immunogenic spike protein of SARS-CoV-2

Netherlands Partnership to Develop an Intranasal COVID-19 Vaccine

The Gavi advance market commitment for COVID-19 vaccines is a new financing instrument aimed at incentivizing vaccine manufacturers to produce sufficient and affordable quantities of COVID-19 vaccines.

Formulation and Drug Delivery